SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 4366.
  • 2
    Schiller JH,Harrinton D,Sandler A, et al. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc ASCO. 2000; 19: 1a.
  • 3
    Belani CP,Langer C. First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer. 2002; 38( suppl 4): 1319.
  • 4
    Le Chevalier T,Pujol JL,Douillard JY, et al. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis. Semin Oncol. 1994; 21(5 suppl 10 ): 2833; discussion 33–34.
  • 5
    Bonomi P,Kim K,Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000; 18: 623631.
  • 6
    Sandler AB,Nemunaitis J,Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000; 18: 122130.
  • 7
    Kelly K,Crowley J,Bunn PAJr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001; 19: 32103218.
  • 8
    Keller SM,Vangel MG,Adak S, et al. The influence of sex on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. Lung Cancer. 2002; 37: 303309.
  • 9
    Scagliotti GV,De Marinis F,Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002; 20: 42854291.
  • 10
    Georgoulias V,Samonis G,Papadakis E, et al. Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer. 2001; 34( suppl 4): S47S51.
  • 11
    Alberola V,Camps C,Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol. 2003; 21: 32073213.
  • 12
    Comella P,Filippelli G,De Cataldis G, et al. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol. 2007; 18: 324330.
  • 13
    Herbst RS,Giaccone G,Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol. 2004; 22: 785794.
  • 14
    Herbst RS,Prager D,Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23: 58925899.
  • 15
    Giaccone G,Herbst RS,Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol. 2004; 22: 777784.
  • 16
    Fuster LM,Sandler AB. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. Clin Lung Cancer. 2004; 6( suppl 1): S24S29.
  • 17
    Langer CJ,Manola J,Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002; 94: 173181.
  • 18
    Balducci L,Extermann M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer. 1997; 80: 13171322.
  • 19
    Lilenbaum R. Management of advanced non-small-cell lung cancer in elderly populations. Clin Lung Cancer. 2003; 5: 169173.
  • 20
    Travis W,Colby T,Corrin B, et al. World Health Organization: Histological Typing of Lung Cancer and Pleural Tumors. 3rd ed. Berlin: Springer; 1999.
  • 21
    Trotti A,Byhardt R,Stetz J, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000; 47: 1347.
  • 22
    Extermann M,Chen H,Cantor AB, et al. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer. 2002; 38: 14661473.
  • 23
    Maione P,Perrone F,Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol. 2005; 23: 68656872.
  • 24
    Audisio RA,Ramesh H,Longo WE,Zbar AP,Pope D. Preoperative assessment of surgical risk in oncogeriatric patients. Oncologist. 2005; 10: 262268.
  • 25
    Eberhardt B,Dilger S,Musial F,Wedding U,Weiss T,Miltner WH. Medium-term effects of chemotherapy in older cancer patients. Support Care Cancer. 2006; 14: 216222.
  • 26
    Lawton MP,Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontology. 1969; 9: 179186.
  • 27
    Lawton MP,Moss M,Fulcomer M,Kleban MH. A research and service oriented multilevel assessment instrument. J Gerontol. 1982; 37: 9199.
  • 28
    Katz S,Ford AB,Moskowitz RW,Jackson BA,Jaffe MW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963; 185: 9499.
  • 29
    Frasci G,Lorusso V,Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000; 18: 25292536.
  • 30
    Extermann M,Overcash J,Lyman GH,Parr J,Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998; 16: 15821587.
  • 31
    Miller MD,Paradis CF,Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992; 41: 237248.
  • 32
    Parmelee PA,Thuras PD,Katz IR,Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc. 1995; 43: 130137.
  • 33
    Charlson ME,Pompei P,Ales KL,MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373383.
  • 34
    Charlson M,Szatrowski TP,Peterson J,Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47: 12451251.
  • 35
    Linn BS,Linn MW,Gurel L. Cumulative Illness Rating Scale. J Am Geriartr Soc. 1968; 16: 622626.
  • 36
    Duffaud F,Therasse P. [New guidelines to evaluate the response to treatment in solid tumors.] Bull Cancer. 2000; 87: 881886.
  • 37
    Kaplan EL,Meier PL. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 38
    Holford TR. Life tables with concomitant information. Biometrics. 1976; 32: 587597.
  • 39
    Grossi F,Tiseo M. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC). Crit Rev Oncol Hematol. 2006; 58: 221230.
  • 40
    Hotta K,Inoue A,Kiura K,Ueoka H,Nukiwa T,Tanimoto M. Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study. Lung Cancer. 2005; 50: 413415.
  • 41
    Argiris A,Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer. 2004; 43(3): 317322.
  • 42
    Hayat MJ,Howlader N,Reichman ME,Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2007; 12: 2037.
  • 43
    Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist. 2001; 6( suppl 1): 47.
  • 44
    Gridelli C,Gallo C,Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003; 21: 30253034.
  • 45
    Lilenbaum RC,Herndon JE2nd,List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005; 23: 190196.
  • 46
    Jackman DM,Yeap BY,Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients ≥ 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007; 25: 760766.
  • 47
    Pham D,Kris MG,Riely GJ, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol. 2006; 24: 17001704.
  • 48
    Fukuoka M,Yano S,Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003; 21: 22372246.
  • 49
    Kris MG,Natale RB,Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290: 21492158.
  • 50
    Simon GR,Ruckdeschel JC,Williams C, et al. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control. 2003; 10: 388395.
  • 51
    Wisnivesky JP,Halm EA. Sex differences in lung cancer survival: do tumors behave differently in elderly women? J Clin Oncol. 2007; 25: 17051712.